Piramal Pharma Share Price in Focus Amid Strong Q2 Results and CDMO Growth

As of November 4, 2024, 01:57 PM, Piramal Pharma Ltd’s stock is trading at ₹274.40, down by 2.64% for the day. It has given 5.58% in the last 5 days and 19.63% in the last 1 month following its stronger-than-expected performance in the second quarter of FY 2024-25. This growth was largely driven by increased demand in its Contract Development and Manufacturing Organization (CDMO) segment.

Financial Highlights 

Piramal Pharma reported strong Q2 financial results. The company’s revenue grew significantly, up 17.28% compared to the same period last year, while its profit soared by 350%. Compared to the previous quarter, revenue increased by 14.89%, and profit jumped by 125.49%, highlighting the impact of its effective strategies and market position.

The company managed to reduce its Selling, General & Administrative (SG&A) expenses by 3.48% from the last quarter, though these costs rose by 8.43% year-over-year as part of its growth efforts. Operating income also showed impressive growth, rising 41.83% from the previous quarter and 21.27% year-over-year, reflecting strong operational performance. For Q2 FY25, Earnings Per Share (EPS) reached ₹0.17, a remarkable 325% increase compared to the same period last year.

About Piramal Pharma Limited

Piramal Pharma Limited (PPL), part of the Piramal Group, has 3 main business divisions: contract development and manufacturing (CDMO), complex hospital generics (for critical care), and consumer healthcare (over-the-counter products). The company entered the pharmaceutical industry in 1988 by acquiring Nicholas Laboratories and has since expanded through multiple mergers, acquisitions, and internal growth efforts. In 2010, PPL sold its domestic formulations business to Abbott for $3.7 billion, and its diagnostic services division was sold to Super Religare Laboratories (SRL).

On November 04, 2024, the Piramal Pharma Ltd share price opened at ₹284.30 and touched the day low of ₹271.35 at 01:49 PM on the NSE. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.